Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;55(1):212-227.
doi: 10.1007/s43441-020-00207-2. Epub 2020 Sep 21.

Drivers of Start-Up Delays in Global Randomized Clinical Trials

Jennifer Lai  1 , Leila Forney  2 , Daniel L Brinton  2 , Kit N Simpson  2
Affiliations

Drivers of Start-Up Delays in Global Randomized Clinical Trials

Jennifer Lai et al. Ther Innov Regul Sci. 2021 Jan.

Abstract

Background: Global, randomized clinical trials are extremely complex. Trial start-up is a critical phase and has many opportunities for delay which adversely impact the study timelines and budget. Understanding factors that contribute to delay may help clinical trial managers and other stakeholders to work more efficiently, hastening patient access to potential new therapies.

Methods: We reviewed the available literature related to start-up of global, Phase III clinical trials and then created a fishbone diagram detailing drivers contributing to start-up delays. The issues identified were used to craft a checklist to assist clinical trial managers in more efficient trial start-up.

Results: We identified key drivers for start-up delays in the following categories: regulatory, contracts and budgets, insurance, clinical supplies, site identification and selection, site activation, and inefficient processes/pitfalls.

Conclusion: Initiating global randomized clinical trials is a complex endeavor, and reasons for delay are well documented in the literature. By using a checklist, clinical trial managers may mitigate some delays and get clinical studies initiated as soon as possible.

Keywords: Best practices; Global clinical trials; Performance; Process optimization; Study start-up; Trial efficiency.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts were declared.

Figures

Figure 1
Figure 1
Key Drivers for Study Start-up Delay in Global, Randomized Clinical Trials.
Figure 2
Figure 2
Sponsor Study Start-up Checklist for Global, Randomized Clinical Trials.
Figure 2
Figure 2
Sponsor Study Start-up Checklist for Global, Randomized Clinical Trials.
Figure 2
Figure 2
Sponsor Study Start-up Checklist for Global, Randomized Clinical Trials.
Figure 2
Figure 2
Sponsor Study Start-up Checklist for Global, Randomized Clinical Trials.
Figure 2
Figure 2
Sponsor Study Start-up Checklist for Global, Randomized Clinical Trials.
Figure 2
Figure 2
Sponsor Study Start-up Checklist for Global, Randomized Clinical Trials.
Figure 2
Figure 2
Sponsor Study Start-up Checklist for Global, Randomized Clinical Trials.
Figure 2
Figure 2
Sponsor Study Start-up Checklist for Global, Randomized Clinical Trials.
Figure 2
Figure 2
Sponsor Study Start-up Checklist for Global, Randomized Clinical Trials.
See this image and copyright information in PMC

References

    1. BioWorld. Clinical Trials of Biopharma and Med-tech Products Affected by COVID-19. https://www.bioworld.com/COVID19clinical-affect. Accessed 04 May 2020.
    1. Sullivan GM. Getting off the "gold standard": randomized controlled trials and education research. J Grad Med Educ. 2011;3(3):285–289. doi: 10.4300/JGME-D-11-00147.1. - DOI - PMC - PubMed
    1. Umscheid C, Margolis D, Grossman C. Key concepts of clinical trials: a narrative review. Postgrad Med. 2011;123(5):194–204. doi: 10.3810/pgm.2011.09.2475. - DOI - PMC - PubMed
    1. da Silva RE, Amato AA, Guilhem DB, Novaes MRCG. Globalization of clinical trials: ethical and regulatory implications. Int J Clin Trials. 2016;3:1–8. doi: 10.18203/2349-3259.ijct20160472. - DOI
    1. Crow RA, Hart KA, McDermott MP, Tawil R, Martens WB, Herr BE, et al. A checklist for clinical trials in rare disease: obstacles and anticipatory actions—lessons learned from the FOR-DMD trial. Trials. 2018;19(1):291. doi: 10.1186/s13063-018-2645-0. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources